看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 11.0x - 12.2x | 11.6x |
| Selected Fwd Revenue Multiple | 1.6x - 1.8x | 1.7x |
| Fair Value | $4.79 - $5.69 | $5.24 |
| Upside | 16.3% - 38.2% | 27.2% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Cumberland Pharmaceuticals Inc. | CPIX | NasdaqGS:CPIX |
| RedHill Biopharma Ltd. | RDHL | NasdaqCM:RDHL |
| 4Front Ventures Corp. | FFNT.F | PINC:FFNT.F |
| Harmony Biosciences Holdings, Inc. | HRMY | NasdaqGM:HRMY |
| Evolus, Inc. | EOLS | NasdaqGM:EOLS |
| Phathom Pharmaceuticals, Inc. | PHAT | NasdaqGS:PHAT |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| CPIX | RDHL | FFNT.F | HRMY | EOLS | PHAT | |||
| NasdaqGS:CPIX | NasdaqCM:RDHL | PINC:FFNT.F | NasdaqGM:HRMY | NasdaqGM:EOLS | NasdaqGS:PHAT | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | 1.9% | 5.0% | 91.7% | 160.2% | 50.1% | NM- | ||
| 3Y CAGR | 1.7% | -54.6% | 19.1% | 32.8% | 38.8% | NM- | ||
| Latest Twelve Months | -4.3% | 23.2% | -27.5% | 22.8% | 31.8% | 8001.5% | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | -18.3% | -204.8% | -33.7% | 0.1% | -63.9% | -7333.4% | ||
| Prior Fiscal Year | -15.7% | -350.2% | -7.0% | 33.0% | -17.9% | -24532.6% | ||
| Latest Fiscal Year | -17.0% | -152.4% | -21.2% | 26.7% | -10.2% | -502.2% | ||
| Latest Twelve Months | -17.0% | -152.4% | -29.3% | 26.7% | -10.2% | -502.2% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 1.86x | -0.03x | 2.99x | 1.79x | 2.87x | 9.59x | ||
| EV / LTM EBIT | -11.0x | 0.0x | -10.2x | 6.7x | -28.0x | -1.9x | ||
| Price / LTM Sales | 1.80x | 0.50x | 0.04x | 2.34x | 2.71x | 4.93x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | -0.03x | 1.86x | 2.99x | |||||
| Historical EV / LTM Revenue | 9.59x | 9.59x | 9.59x | |||||
| Selected EV / LTM Revenue | 11.01x | 11.59x | 12.17x | |||||
| (x) LTM Revenue | 55 | 55 | 55 | |||||
| (=) Implied Enterprise Value | 608 | 641 | 673 | |||||
| (-) Non-shareholder Claims * | (258) | (258) | (258) | |||||
| (=) Equity Value | 351 | 383 | 415 | |||||
| (/) Shares Outstanding | 68.4 | 68.4 | 68.4 | |||||
| Implied Value Range | 5.13 | 5.60 | 6.07 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 5.13 | 5.60 | 6.07 | 4.12 | ||||
| Upside / (Downside) | 24.5% | 35.9% | 47.3% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | CPIX | RDHL | FFNT.F | HRMY | EOLS | PHAT | |
| Enterprise Value | 70 | (0) | 231 | 1,294 | 777 | 539 | |
| (+) Cash & Short Term Investments | 18 | 5 | 1 | 467 | 87 | 297 | |
| (+) Investments & Other | 0 | 0 | 0 | 109 | 0 | 0 | |
| (-) Debt | (21) | (0) | (230) | (181) | (130) | (555) | |
| (-) Other Liabilities | 0 | 0 | (0) | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 68 | 4 | 2 | 1,689 | 734 | 282 | |
| (/) Shares Outstanding | 14.0 | 1.8 | 916.4 | 57.4 | 63.6 | 68.4 | |
| Implied Stock Price | 4.85 | 2.32 | 0.00 | 29.43 | 11.55 | 4.12 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 4.85 | 2.32 | 0.00 | 29.43 | 11.55 | 4.12 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |